



Radiation Therapy
Oncology Group

RTOG Report to ATC



Radiation Therapy Oncology Group



AMERICAN ASSOCIATION OF
PHYSICISTS IN MEDICINE



Radiological Physics Center

RCET

University of Florida
Radiation Oncology

QARC

Quality Assurance
Review Center





Radiation Therapy
Oncology Group

RTOG Headquarters Report

RTOG Protocols supported by the ATC (as of January 12, 2005)

- 11 Studies (7 Active / 4 closed, data analysis continues)
 - RTOG 94-06: Phase I/II Dose Escalation Study Using 3D Conformal Radiation Therapy for Adenocarcinoma of the Prostate
 - 54 institutions credentialed; 1084 patients registered to study (study closed, data analysis continues)
 - RTOG 93-11: Phase I/II Dose Escalation Study Using 3D Conformal Radiation Therapy in Patients with Inoperable NSCLC
 - 27 institutions credentialed; 180 patients registered to study (study closed, data analysis continues)
 - RTOG 98-03: Phase I/II Radiation Dose Escalation Study Applying Conformal Radiation Therapy in Supratentorial Glioblastoma Multiforme
 - 46 institutions credentialed; 210 patients registered to study (study closed, data analysis continues)



Radiation Therapy
Oncology Group

RTOG Headquarters Report (cont.)

RTOG Protocols supported by the ATC (as of January 12, 2005) (cont.)

- RTOG 0319: Phase I/II Study to Evaluate 3DCRT Irradiation Confined to Region of the Lumpectomy Cavity for Stage I/IIA Breast Carcinoma
 - 31 institutions credentialed; 58 patients registered to study; Target Accrual – 46 (study closed, data analysis continues)

- RTOG 0022: Phase I/II Study of Conformal And Intensity Modulated Irradiation for Oropharyngeal Cancer
 - 31 institutions credentialed; 67 patients registered to study; Target Accrual – 64

- RTOG 0117: Phase I/II Dose Intensification Study using 3DCRT and Concurrent Chemotherapy for Patients with Inoperable, Non-Small Cell Lung Cancer
 - 39 institutions credentialed; 20 patients registered to study; Target Accrual – 73



Radiation Therapy
Oncology Group

RTOG Headquarters Report (cont.)

RTOG Protocols supported by the ATC (as of January 12, 2005) (cont.)

- RTOG 0126: Phase III Randomize Study of High Dose 3DCRT/IMRT versus Standard Dose 3DCRT/IMRT in Patients treated for Localized Prostate Cancer (9/18/03 IMRT allowed)
 - 108 institutions credentialed; 448 patients registered to study; Target Accrual – 1520
- RTOG 0225: Phase I/II Study of Conformal And Intensity Modulated Irradiation for Nasopharyngeal Cancer
 - 31 institutions credentialed; 38 patients registered to study; Target Accrual – 64
- RTOG 0232: Phase III Study Comparing Combined External Beam Radiation & Transperineal Interstitial Permanent Brachytherapy with Brachytherapy alone
 - 50 institutions credentialed; 86 patients registered to study; Target Accrual – 1520



Radiation Therapy
Oncology Group

RTOG Headquarters Report (cont.)

RTOG Protocols supported by the ATC (as of January 12, 2005) (cont.)

- RTOG 0236: Phase II Study of Extracranial Stereotactic Radioablation in Treatment of Patients with Medically Inoperable Stage in NSCLC
 - 3 institutions credentialed; 3 patients registered to study; Target Accrual – 52
- RTOG 0321: Phase I/II Prostate: High Dose Brachytherapy and External Beam
 - 2 institutions credentialed; 1 patients registered to study; Target Accrual – 110



Radiation Therapy
Oncology Group

RTOG Headquarters Report (cont.)

Pending RTOG Protocols (ATC Resources Requested/Committed)

- 9 Studies
 - RTOG 0515(0238): A Phase I/II Study of Gross Tumor Volume Definition with or without Pet Fusion for Patients with Non-Small Cell Lung Carcinoma
 - RTOG 0438(0245): Phase I Study Highly Conformal Radiation Therapy for Patients with Unresectable Primary Hepatobiliary Cancer and Liver Metastases
 - RTOG 0413/NSABP B39: Phase III Study of Whole Breast RT versus Partial Breast Irradiation
 - RTOG 0415: Phase III Randomized Study of Hypofractionated 3DCRT/IMRT vs. Conventionally Fractionated 3DCRT/IMRT in Patients treated for Favorable Risk Prostate Cancer (on hold)



Radiation Therapy
Oncology Group

RTOG Headquarters Report (cont.)

Pending RTOG Protocols (ATC Resources Requested/Committed) (cont.)

- RTOG 0417: Phase II Study of Iressa in Combination with Definitive RT and Cisplatin Chemo in Locally Advanced Cervical Cancer, Optional Brachy/CT
- RTOG 0418: Phase II Study of IMRT to the Pelvis +/- Chemotherapy for Post-operative Patients with either Endometrial or Cervical Carinoma
- RTOG 0421: Phase III Head & Neck: Re-irradiation (GCSF)/IMRT
- RTOG 0436: Phase III Esophagus, Cetux./Cis/RT then Surgery vs. Cis/Taxol/RT/Surgery (discussion to allow IMRT)
- RTOG 0522: Phase III Advanced Unresectable Head & Neck RT+Cis vs. RT+Cis+C225/IMRT



Radiation Therapy
Oncology Group

ATC Review Workstation at RTOG HQ's in Philadelphia, PA





Radiation Therapy
Oncology Group

IMAGE-GUIDED THERAPY CENTER [ITC]

Protocol RTOG-P0126 Dose-Volume Analysis QA Review for: Cross Cancer Institute

Patient Initials: P. W. Case #: 9 0126c0009

Group: 2 Dose Level: _____ Rx Dose: 72.93 (See Appendix I)

A. TARGET VOLUME ANALYSIS

Target	Volume (cc)	Percent Volume Receiving \geq Rx Dose(D1)	ICRU Ref Dose (Gy)	2% Max Dose (Gy)	Min Dose (Gy)	Mean Dose (Gy)	Coverage Score
PTV1	310	100 % \geq 55.8 Gy	73.0	74.4	57	73	1
PTV2	242.4	100 % \geq 70.2 Gy		74.4	68	73.4	1
PTV	---	--- % \geq --- Gy	"	---	---	---	---
CTV	113	99.3 % \geq 70.2 Gy	"	74.4	65.4	74	1
GTV	89	100 % \geq 70.2 Gy		74.2	72	74	1

Target Volume Coverage Score: 1: $V_{RxD} \geq 98\%$, 2: $95\% \leq V_{RxD} < 98\%$, 3: $V_{RxD} < 95\%$ or $V_{RxDCTV \text{ or } GTV} < 100\%$.

B. DOSE HETEROGENEITY(DH) And CONFORMITY

	Conformity Index*	Dose Heterogeneity	Dose Heterogeneity Score
PTV(2)	---	1.02 ✓	1

Dose Heterogeneity (2% Max Dose/Rx dose): 1: $DH \leq 1.07$, 2: $1.07 < DH \leq 1.10$, 3: $DH > 1.10$

C. NORMAL STRUCTURE ANALYSIS (See appendix II for standard structure names)

Normal Tissue	Volume (cc)	% Vol \geq Ref Dose (D1)	Ref Dose (D1) (Gy)	Max Dose (Gy)	Mean Dose (Gy)
Bladder	112	50	65.0	74.4	61.1
Left Femur	192	0	52.0	41	34.4
Right Femur	187	0	52.0	42	33.0
Rectum	87	30	60.0	74.3	49
Penile Bulb	9.3	55.2	70.0	73	68
Unspecified Tissue	23710	0.9	58.9	74.4	8

Reviewed by: lquarles Date: 12-1-04

After completing this form please FAX to the ITC: (314)747-5423.



Radiation Therapy
Oncology Group

Image-guided Therapy Center

Protocol: 0126 Case: 0009 (Plan ID: totalhetero) Plan Date: Mon Nov 18 11:06:31 2005
Plan Description: composite plan

Calculation Volume Size: Width(x) 42.3(cm) x Depth(y) 28.8(cm) x Height(z) 26.1(cm) [142 x 145 x 88]
Center: X = 0.8, Y = -2.1, Z = 3.1 SITE: Prostate MD: cross

Beam # (Field):	1 (_____)	2 (_____)	3 (_____)	4 (_____)
Description:	>Ant (B1)	>Post (B2)	>Right (B3)	>Left (B4)
Machine ID:	15MVXRAYS	15MVXRAYS	15MVXRAYS	15MVXRAYS
Setup Distance:	100.0 cm SAD	100.0 cm SAD	100.0 cm SAD	100.0 cm SAD
Isocenter Depth:	ODI(_____) 11.4 cm	ODI(_____) 12.5 cm	ODI(_____) 20.4 cm	ODI(_____) 20.1 cm
Isocenter Coord:	0.8, -3.9, 2.7 cm	0.8, -3.9, 2.7 cm	0.8, -3.9, 2.7 cm	0.8, -3.9, 2.7 cm
Entry Point:	0.8, -3.9, 14.1 cm	0.8, -3.9, -9.8 cm	-19.5, -3.9, 2.7 cm	20.9, -3.9, 2.7 cm
Coll. Width(cone):	X1: 5.0 cm X2: 5.0 cm	X1: 5.2 cm X2: 5.1 cm	X1: 4.8 cm X2: 4.1 cm	X1: 4.0 cm X2: 5.0 cm
Coll. Length(cone):	Y1: 6.3 cm Y2: 6.1 cm	12.5 cm	12.5 cm	Y1: 6.3 cm Y2: 6.2 cm
Collimator Angle:	180 degrees	180 degrees	180 degrees	180 degrees
Couch Angle:	180 degrees	180 degrees	180 degrees	180 degrees
Head/Foot Orient:	Head to Gantry	Head to Gantry	Head to Gantry	Head to Gantry
Gantry Angle:	180 degrees	360 degrees	270 degrees	90 degrees
Rotation Arc:	x x x	x x x	x x x	x x x
Comp Filter Used:	NO COMPENSATOR			
Bolus Used:	NO BOLUS USED	NO BOLUS USED	NO BOLUS USED	NO BOLUS USED
Wedge (Normal):				
Wedge Orientation:				
ICRU Ref Pt (cGy):	1739 TD	1739 TD	1159 TD	1162 TD
Films Link/Aligned:	_____	_____	_____	_____

Page# 1 of 2 [Max Point Dose = 7472] Plan Info (Total ICRU Dose: 7296 [Sampled Dose Value: 7300])





Radiation Therapy
Oncology Group


Image-guided Therapy Center

PROTOCOL: 0126

CASE: 0009

STRUCTURE: PTV1

Remote Review Tool



Plan ID	% Vol >= D1 (55.8 Gy)	% Vol >= Dref (55.8 Gy)	Max Dose (Gy)	Min Dose (Gy)	Mean Dose (Gy)
totalhetero	100.0	100.0	74.7	56.9	72.7

Calculated: Fri Apr 16 14:08:26 2004 (/web/RTOP/patient/0126c0009/olddump.dat)

Printed Fri Jan 14 09:48:51 CST 2005

[Close window](#)



Radiation Therapy
Oncology Group

IMAGE-GUIDED THERAPY CENTER [ITC]

Protocol H0022 Dose-Volume Analysis QA Review for:

Patient Name: 0013 Physician: _____

Institution: _____ QA Center ID: _____

A. TARGET VOLUME ANALYSIS

Targ. Vol.	Volume (cc)	% Vol ≥ Rx Dose		% Vol > 110% Rx Dose		% Vol ≥ X% of Rx Dose (Gy)		% Vol ≥ Y% of Rx Dose		Max. Dose Gy	Min Dose Gy	Mean Dose Gy	Score
PTV66	42	100	66.0	7.3	72.6	100	61.4	X		75	62.2	70.3	1
PTV54	492	95.3	54.0	38	59.4	100	47.0	0	72.6	74.4	29.4	59	1

Scoring is: 1 – No Variation; 2 – Minor Variation; 3 – Major Variation [The volume of PTV66 MUST be subtracted out of the PTV54 DVH]

B. DOSIMETRIC SCORE

Score	PTV66 Dose Coverage			PTV54 Dose Coverage		
1	95% of PTV66 ≥ 66 Gy	99% of PTV66 ≥ 60.0 Gy	80% of PTV66 ≤ 72.6 Gy	95% of PTV54 ≥ 54 Gy	99% of PTV54 ≥ 50.2 Gy	80% of PTV54 ≤ 59.4 Gy
2	90% of PTV66 ≥ 66 Gy	99% of PTV66 ≥ 60.0 Gy	75% of PTV66 ≤ 72.6 Gy	90% of PTV54 ≥ 54 Gy	99% of PTV54 ≥ 47.0 Gy	80% of PTV54 ≤ 72.6 Gy
3	<90% of PTV66 ≥ 66 Gy	<99% of PTV66 ≥ 60.0 Gy	<75% of PTV66 ≤ 72.6 Gy	<90% of PTV54 ≥ 54 Gy	<99% of PTV54 ≥ 47.0 Gy	<80% of PTV54 ≤ 72.6 Gy

C. NORMAL STRUCTURE ANALYSIS

Target Volume	Volume (cc)	% Vol. ≥ Reference Dose	Max. Dose (Gy)	Mean Dose (Gy)	Constraint(s) Met	Score
Parotid Lt	40.1	26.4	30.0 Gy	58	22.4	<input type="checkbox"/> Y <input type="checkbox"/> N
Parotid Rt	37.3	93	30.0 Gy	71.2	50.2	<input type="checkbox"/> Y <input type="checkbox"/> N
Parotid Total	77.3	72	20.0 Gy	71.2	36	<input type="checkbox"/> Y <input type="checkbox"/> N
Mandible	62.3	1.1	70.0 Gy	73	35.1	<input type="checkbox"/> Y <input type="checkbox"/> N
Larynx	3	0	50.0 Gy	43.2	23	<input type="checkbox"/> Y <input type="checkbox"/> N
Brain Stem	29	0	54.0 Gy	50	7.1	<input type="checkbox"/> Y <input type="checkbox"/> N
Spinal Cord	13.1	0	45.0 Gy	40	17	<input type="checkbox"/> Y <input type="checkbox"/> N
Non-Target Tissue	11774	1	58.9 Gy	73	12	<input type="checkbox"/> Y <input type="checkbox"/> N
Composite Score						1

Score	Parotid Sparing		
1	Mean dose to either gland < 26 Gy	or	50% of either gland ≤ 30 Gy
2	≤ 60% of either gland ≤ 30 Gy		
3	60% of either gland > 30 Gy		

Composite score is maximum of coverage and parotid sparing scores.

Reviewed by: Iquarles

Date of Review: 10-29-04


Rev. 20Mar02



Radiation Therapy
Oncology Group

RTOG 0232

Prostate – Brachytherapy Credentialing Process Notification





Radiation Therapy
Oncology Group

Institution Approval Letter for RTOG – 0232



Radiation Therapy Oncology Group

American College of Radiology
1101 Market Street, 14th Floor
Philadelphia, PA 19107
(215) 574-3189
(800) 227-5463 Ext. 4189
(215) 928-0153 Fax

Date

Radiation Oncologist, M.D.
Institution – CTSU
Address
City, State, Zip Code

Dear Dr.:

The Credentialing process by the Radiological Physics Center (RPC) for prostate brachytherapy and Electronic Data Submission to the Image-Guided Therapy Center (ITC) for RTOG-0232 – A Phase III Study Comparing Combined External Beam Radiation and Transperineal Interstitial Permanent Brachytherapy with Brachytherapy Alone for Selected Patients with Intermediate Risk Prostatic Carcinoma has been successfully met.

You are now approved to enter patients onto RTOG Prostate Implant Protocol 0232. A change in Radiation Oncologist, Physicist, treatment planning system, nuclide or seed model will require recredentialing by the RPC and/or ITC.

Sincerely,

Elizabeth A. Martin
Director, R.T. Quality Assurance

cc: Physicist
Research Associate
Dosimetrist
RTOG Randomization
ITC
RPC
CTSU



Radiation Therapy
Oncology Group

Credentialed Institutions

RTOG – 0232 (50 Institutions Credentialed)

RTOG Inst. #	RTF #	Name	Source	Approved	Physician	Physicist	TX Planning Sys.	Dry Run Sub. ITC	Dry Run Approval
RTOG Protocol P-0232									
	2650	Vanderbilt	I-plant	05/05/03	Ming Teng	Charles Coffey, Bob Aus	Rosses		
7718	1192	Univ. of TX, San Antonio (Can. Ther. Res. Ctr)	logold, prostaseed, pd200, pdgold, best pd	05/16/03	Bradley Prestidge	William Bice	Home Grown and Variseed		
5922	1775	Mary Bird Perkins		07/18/03	Sheldon A. Johnson	Angela Stam	Varian Variseed		
2102		Washington University Medical Center		07/18/03	Jeff Michalski		Varian Variseed		
3401	2215	Roswell Park Cancer Institute		08/06/03	Michael Kuettel	Matthew Podgorsak	Varian Variseed		
	2687	Wake Forest University Baptist Med. Ctr.		09/04/03	W. Robert Lee	Allan deGuzman	Varian Variseed		
1518	1011	Akron City Hospital		09/29/03	Michael Seider	Stanley Phillips	Varian Variseed		
2501	1675	LDS Hospital		10/27/03	R. J. Lee, M.D.	David Matthes			
0137	2700	Washoe Medical Center		11/04/03	Lawrence Dardick, M.D.	Richard Erickson, M.S.	Varian Variseed		
5803	2805	South Suburban Oncology Center		11/14/03	H. Joseph Barthold, M.D.	Sheri Weintraub, M.S.	Varian Variseed		
7501		Cross Cancer Institute		11/14/03	John Pedersen, M.D.	Ron Sloboda, Ph.D.	Varian Variseed		
	0152	Hospital of St. Raphael		11/18/03	Joseph Cardinale, M.D.	Per Halvorsen, M.S.	Varian Variseed		
CTSU		Memorial Medical Center		12/05/03	Francis Cardinale, M.D.	Randy Maxey, M.S.	Varian Variseed		
	2215	Princess Margaret Hospital		12/31/03	Thomas Shanahan, M.D.	Ivan Yeung	Varian Variseed		
	0184	Mayo Clinic		01/14/04	Juanita Crook, M.D.	Robert W. Kline, Ph.D.			
	6201	Radiological Associates of Sacramento		01/21/04	Michael McLean, M.D.	Luke McLemore, M.S.	Varian Variseed		
	5301	2120 Queen's Medical Center in Honolulu		02/02/04	Brian J. Davis, M.D.	C. Robert Blackwell, M.S.	Amersham model 6711		
	0629	York Cancer Center, Wellspan		02/11/04	Seth Rosenthal, MD	Jadwiga B. Wojcicka, Ph.D.	Varian Variseed		
	9610	McKay Dee Hospital Center		02/12/04	David Instadt, MD	Stephan Both, M.S.	Varian Variseed		
	5702	University of Maryland Medical Systems		02/16/04	Mark Leibenhaut, MD	Mark Arnfield, Ph.D.	Varian Variseed		
	3701	1021 Allegheny General Hospital		03/15/04	Pradip Amin, M.D.	Mehrdad Sarfaraz, Ph.D.	Varian Variseed		
	5901	1744 Univ of TX-MD Anderson Cancer Center		03/31/04	William Regine, M.D.	Ann Lawyer, M.S.	Varian Variseed		
	2426	1914 Mount Diablo Medical Center		03/31/04	Russell Fuhrer, M.D.	Ram Virudachalam, Ph.D.	Varian Variseed		
	0180	1918 Mt. Sinai Comprehensive Can. Ctr.		04/14/04	Derek L. Shickell, M.D.	Erias Gete, Ph.D.	Varian Variseed		
	7015	2704 Waukesha Memorial Hospital		05/07/04	Leonard Toonkel, M.D.	Francis Chang, Ph.D.	Varian Variseed		
	5101	1016 Albert Einstein Medical Center		05/07/04	Wingate Clapper, M.D.	Eric Hendee, M.S.	Varian Variseed		
	0601	1451 Frankford Hospital		05/07/04	Kenneth Zeitzer, M.D.	Feng Zhou, M.S.	Varian Variseed		
	0601	1640 Thomas Jefferson University Hospital		05/07/04	Eric Gressen, M.D.	Jinyu Xue, Ph.D.	Varian Variseed		
	9520	1788 McGuire Veterans Admin. Med. Ctr.		05/10/04	Adam Dicker, M.D.	Richard Valicenti, M.D.	Varian Variseed		
	0488	1512 H. Lee Moffitt Cancer Center		05/28/04	Richard Hudes, M.D.	Hayeon Kim, M.S.	Varian Variseed		
	2217	1066 Baptist Medical Center		05/28/04	Michael Hagan, M.D.	Nirmal Sakthi	Varian Variseed		
	8201	2619 University of Utah Hospital & Clinics		05/28/04	Anthony Addesa, M.D.	Amarjit S. Saini, M.S.	Varian Variseed		
	5710	2344 St. Agnes Cancer Center		06/01/04	Randy Heysek, M.D.	Norman Brown, M.S.	Varian Variseed		
	1524	1104 Beth Israel Medical Center		06/29/04	Douglas Johnson, M.D.	Jim Rankin	Varian Variseed		
					Dennis C. Shrieve, M.D.	Timothy Holmes, Ph.D.	Varian Variseed		
					Daniel Shasha, M.D.	Lin Wang, M.S.	Varian Variseed		



Radiation Therapy
Oncology Group

Credentialed Institutions (cont.)

RTOG – 0232 (50 Institutions Credentialed)


RTOG Inst. #	RTF #	Name	Source	Approved	Physician	Physicist	TX Planning Sys.	Dry Run Sub. ITC	Dry Run Approval
2417	1166	California Cancer Center		07/22/04	Douglas Wong, M.D.	Georg Weidlich, Ph.D.	Varian Variseed		
0526	2597	University of Kentucky		07/23/04	William St.Clair, M.D.	Ali Meigooni, Ph.D.	Varian Variseed		
7001	1460	Medical College of Wisconsin		08/06/04	Colleen Lawton, M.D.	Paul Jursinic, Ph.D.	Varian Variseed		
7002	1294	Community Memorial Hospital		08/11/04	Colleen Lawton, M.D.	Paul Jursinic, Ph.D.	Varian Variseed		
CTSU	1203	Capital Health System - Mercer Campus		08/23/04	Daniel K. Fram, M.D.	Gregory Desobry, Ph.D.	Varian Variseed		
						Andrew Jones, Ph.D.			
0181	1463	Geisinger Medical Center		08/23/04	Omar Yumen, M.D.	Caria Setto Scofield, M.S.	Varian Variseed		
7016	2450	St. Mary's Regional Cancer Center		09/01/04	Doug Rock, M.D.	Larry Pallas, M.S.	Varian Variseed		
						Jose Garcia-Cobian, M.S.			
1022	2636	Virtua Memorial Hospital of Burlington County		09/10/04	Lemuel Arlaratnam, M.D.	Daniel Januseski, M.S.	Varian Variseed		
		Gibbs Cancer Center			Patricia Griffin, M.D.	David Vassy, M.S.			
2132	2340	Spartanburg Regional Hospital		09/10/04	Drew Monitto, M.D.	Jim Turmel, M.S.	Varian Variseed		
CTSU	2229	Sacred Heart Medical Center		09/23/04	Gary VanHeuvelen, M.D.	Ray Luse, M.S.	Varian Variseed		
2501	1307	Cottonwood Hospital		10/07/04	R. Jeffrey Lee, M.D.	David Matthes	Varian Variseed		
		2265 Scottsdale Radiation Oncology							
2503	1042	Arrowhead Cancer Center		10/20/04	David Beyer, M.D.	Kevin Rogers, M.S.	Varian Variseed		
0503	2406	Radiation Oncology Associates of Albuquerque		10/28/04	Paul Anthony, M.D.	David Lake, M.S.	Varian Variseed		
					Michael Haake, M.D.				
0528	1210	Carolinas Medical Center		11/17/04	Brad McCall, M.D.	Doug Frank, M.S.	CMS XIO		
					Vidon Donovanik, M.D.				
8918	1256	Christiana Care Health Services		12/16/04	Adam Raben, M.D.	Larry Simpson, Ph.D.	Varian Variseed		
					Albert Yuen, M.D.				
2228	2168	Reading Hospital & Medical Center		12/22/04	Michael Haas, M.D.	Rene Smith, Ph.D.	Varian Variseed		
2401	2403	University of California San Francisco		12/22/04	Mack Roach, M.D.	Barby Pickett			
0501	2613	University of Rochester		12/28/04	Ralph Brasacchio, M.D.	Haisong Liu, Ph.D.	Rtek Piper		



Radiation Therapy
Oncology Group

RTOG 0022

IMRT H&N – Oropharyngeal Credentialing Process Notification






Radiation Therapy
Oncology Group

RTOG 0225

IMRT H&N – Nasopharyngeal

Credentialing Process Notification





Radiation Therapy
Oncology Group

Institution Approval Letter for RTOG – 0022 & 0225



Radiation Therapy Oncology Group

American College of Radiology
1101 Market Street, 14th Floor
Philadelphia, PA 19107
(215) 574-3189
(800) 227-5463 Ext. 4189
(215) 928-0153 Fax

Date

Institution

Dear Dr.:

The IMRT Head and Neck Phantom irradiation component of the credentialing process reviewed by the Radiological Physics Center (RPC) and the testing for the dry run case through the Image-Guided Therapy Center (ITC) for RTOG 0022 – Phase I/II Study of Conformal and Intensity Modulated Irradiation for Oropharyngeal Cancer and RTOG 0225 – Phase II Study of Intensity Modulated Radiation Therapy (IMRT) +/- Chemotherapy for Nasopharyngeal Cancer has been successfully met.

You are now approved to enter patients onto RTOG Protocol 0022 and RTOG 0225.

Sincerely,

Elizabeth A. Martin
Director, R.T. Quality Assurance



Radiation Therapy
Oncology Group

Approved Institutions RTOG – 0022 & 0225

31 Institutions Credentialed 67 Institutions in process

Institution	NCI #	RTOG Inst.#	ITC Dry Run Approval	Digital Phantom Data Submission to ITC	ITC Acceptable	RTF #	Phantom Irradiation	RPC Phantom Approval	RPC Acceptable	Status	Repeats	RPC Acceptable	Overall Approval
Akron City Hospital	OH055	1518	01/07/2005	01/07/2005	Yes	1011	03/04/2004	03/29/2004	Yes	Active			Yes
Albert Einstein Medical Center	PA094	5101				1016	06/01/2004	08/16/2004	Yes	Active			
Albuquerque Regional Medical Center													
Northeast Heights Cancer Center													
Radiation Oncology Associates of Albuquerque	NM001	0503	11/10/2004	11/01/2004	Yes	2406	04/12/2004	05/12/2004	Yes	Active	N/A	N/A	Yes
Alta Bates Comprehensive Cancer Center	CA164	9500				1025	01/07/2005	01/07/2005	Yes	Active			
Baptist Medical Center						1066	06/18/2004	08/04/2004	Yes				
Baptist Hospital of Miami	FL078	8903				1065	01/07/2005	01/07/2005	Yes	Active			
Baylor College of Medicine		7011				1088	05/17/2004	05/17/2004	Yes	Resign-4/1/95			
Beth Israel Deaconess Medical Center	MA038	9641				1103	08/26/2004	10/20/2004	Yes	Active			
California Cancer Center						1166	05/15/2002	08/20/2003	No				
Cancer Center at Saint Agnes	CA112	2431				1182	07/27/2004	08/23/2004	Yes	Active			
Cancer Therapy and Research Center	TX059	7718				1193	06/04/2004	08/31/2004	Yes	Active			
Central Wisconsin Cancer Program (St. Agnes, Wisconsin)	WI060	7013				1231	02/04/2003		No	Resign-12/31/96			
Charleston Radiation Therapy Consultants						1238	05/13/2004	08/16/2004	Yes				
Christiana Care Health System	DE002	8918				1256	06/28/2004	08/13/2004	Yes	Active			
Cleveland Clinic Foundation	OH027	8001				1269	08/10/2004	09/22/2004	Yes	Active			
Community Medical Center	NJ070	2211	07/29/2004	07/29/2004	Yes	1293	01/16/2004	02/13/2004	Yes	Active	N/A	N/A	Yes
Cross Cancer Institute	11104	7501	12/21/2001	12/21/2001	Yes	1313	07/29/2001	1st 10	Yes	Active	N/A	N/A	Yes
Dartmouth-Hitchcock Medical Center	NH012	8902	01/07/2005	01/07/2005	Yes	1325	08/31/2004	10/20/2004	Yes	Active			Yes
Emory Clinic	GA005	1528				1401	06/04/2004	02/12/2004	Yes	Active			
Fairview University Medical Center	MN022	1312				2603	04/28/2004	05/27/2004	Yes	Active			
Falck Cancer Center	NY170	0527				1040	08/31/2004	10/20/2004	Yes	Resign - 4/15/97			
Flower Memorial Hospital		7890				1440	11/02/2002	12/03/2003	Yes	Active			
Fox Chase Cancer Center	PA086	2212				1449	12/02/2002	11/20/2003	No	Active	Repeat - 9/4/03	Yes	
Georgetown University Medical Center	DC005	5487				1471	03/28/2003	06/19/2003	No	Resign-2/21/00			
Geisinger Medical Center	PA052	0181				1483	06/31/2004	09/24/2004	Yes	Active			
Good Samaritan, Portland OR		2133	02/20/2003	05/07/2003	Yes	1483	04/09/2003	06/06/2003	Yes	Resign-10/1/95	Repeat - 7/25/03	Yes	Yes
H. Lee Moffitt Cancer Center	FL079	0488	11/18/2003	11/18/2003	Yes	1512	01/16/2004	03/02/2004	Yes	Active	N/A	N/A	Yes
Holmes Regional Medical Center	FL021	2236				1557	07/17/2002	09/18/2003	No	Resign-1/21/03	Repeat - 7/7/03	Yes	
Intercommunity Cancer Center, Cincinnati, OH						1602	09/19/2003	09/19/2003	Yes	Not a Member			
Iowa Methodist Medical Center	IA004	0200				1626	04/24/2003	06/16/2003	No	Resign-4/15/97	no longer have phantom		
John's Hopkins	MD017	5701	04/03/2003	03/31/2003	Yes	1652	01/20/2003	06/06/2003	Yes	Active	N/A	N/A	Yes
Johns City Medical Center	TN011	5904				1653	02/27/2004	03/18/2004	Yes	Active			Yes
Kansas City Cancer Centers-Southwest (CCOP)	MO058	0126	01/18/2004	01/19/2004	Yes	1654	02/19/2004	03/17/2004	Yes	Active	N/A	N/A	Yes
Kansas City Hospital (North Kansas City Hospital)	MO058	0126	07/29/2004	07/29/2004	Yes	1978	07/28/2004	08/31/2004	Yes	Active	N/A	N/A	Yes
Lankenau Hospital	PA183	0258	05/26/2004	05/26/2004	Yes	1148				Active			
LDS Hospital	UT004	2501				1875	12/12/2003	01/15/2004	Yes	Active			
Lutheran General Hospital	IL010	0722				1732		12/08/2004	Yes				
M.D. Anderson Cancer Center	TX035	5801	11/14/2001	11/14/2001	Yes	1744	04/14/2001	1st 10	Yes	Active	N/A	N/A	Yes
MD Anderson Brazosport						1743	07/07/2004	08/23/2004	Yes				
Mary Bird Perkins Cancer Center	LA002	8802	06/28/2004	06/28/2004	Yes	1775	09/23/2004	05/31/2004	Yes	Active	N/A	N/A	Yes
Massachusetts General Hospital	MA034	5801				1783	05/08/2003	1st 10	Yes	Active			Yes
Mayo Clinic Rochester, MN	MN028	0184	10/18/2004	10/18/2004	Yes	1785	05/20/2003	06/23/2003	Yes	Active	N/A	N/A	Yes
McGill University	11182	1201	03/25/2004	03/25/2004	Yes	1903	12/08/2003	02/04/2004	Yes	Active	N/A	N/A	Yes
McKay-Dee Hospital Center	UT007	9610	11/03/2004	11/03/2004	Yes	2807	03/16/2004	04/13/2004	Yes	Active	N/A	N/A	Yes
McLaren Regional Cancer Center	MI060	2209				1790	06/04/2004	06/04/2004	Yes	Active			
Medical College of Wisconsin	WI013	7001	02/20/2002	02/20/2002	Yes	1460	03/09/2001	1st 10	Yes	Active	N/A	N/A	Yes
Memorial Health University Medical Center						1810			No				
Memorial Sloan-Kettering Cancer Center	NY015	2301	01/06/2004	01/06/2004	Yes	1823	10/31/2003	12/04/2003	Yes	Active	N/A	N/A	Yes
Monmouth Medical Center	NJ068	2242				1897	10/04/2004	12/01/2004	Yes	Active			
Naval Medical Center Portsmouth	VA024	2245				1941	06/16/2003	07/18/2003	Yes	Active			
Northwest Community Hospital	IL001	7705				1941	08/20/2003	12/02/2003	Yes	Active			
Northwestern Memorial Hospital	IL038	2116				2163		07/12/2004	Yes	Active			



Radiation Therapy
Oncology Group

Approved Institutions

RTOG – 0022 & 0225 (cont.)

31 Institutions Credentialed

67 Institutions in process

Institution	NCI #	RTOG Inst.#	ITC Dry Run Approval	Digital Phantom Data Submission to ITC	ITC Acceptable	RTF #	Phantom Irradiation	RPC Phantom Approval	RPC Acceptable	Status	Repeats	RPC Acceptable	Overall Approval
Princess Margaret Hospital	11030	2215				2100	03/12/2004	04/08/2004	Yes	Active			
Queen's Medical Center, Honolulu, Hawaii	HI004	5301				2120	02/25/2003	06/23/2003	Yes	Active			
Radiation Oncology Centers of Las Vegas	NV012	0137	10/13/2004	10/13/2004	Yes	2138	02/24/2004	03/17/2004	Yes	Active	N/A	N/A	Yes
Radiological Associates Sacramento (Sutter)	CA269	6201	05/22/2003	01/10/2003	Yes	2503	10/16/2003	12/05/2003	Yes	Active	N/A	N/A	Yes
Rapid City Regional Hospital	SD006	0206				2163	06/06/2004	07/12/2004	Yes	Active			
Regional Radiology Oncology Center, Rome, GA	GA059	5490				1821	07/01/2004	08/23/2004	Yes	Active			
Robert Wood Johnson University Hospital	NJ053	0633				2913	03/09/2004	04/07/2004	Yes	Active			
Roper Hospital		4512				2212	06/04/2004	06/04/2004	Yes	Active			
Roswell Park Cancer Institute	NY158	3401	04/13/2004	04/13/2004	Yes	2215	11/11/2003	11/11/2003	Yes	Active	N/A	N/A	Yes
Saskatoon Cancer Center	11120	7512	12/10/2001	12/10/2001	Yes	2260	11/09/2001	1st 10	Yes	Active	N/A	N/A	Yes
Sentara Norfolk General Hospital	VA052	5485				2271	11/01/2003	01/13/2004	Yes	Active			
St Luke's Bethlehem, PA	PA054	1324				2433	06/18/2003	07/18/2003	Yes	Active			
Swedish Cancer Institute						2560	11/24/2003	11/24/2003	Yes	Active			
Thomas Jefferson University	PA121	0801	11/14/2001	11/14/2001	Yes	1840	09/28/2000	1st 10	Yes	Active	N/A	N/A	Yes
Thompson Cancer Survival Center	TN038	2111				2530	07/20/2004	09/23/2004	Yes	Resign - 9/5/97			
Tom Baker Cancer Centre	11134	8301	06/23/2003	06/23/2003	Yes	2535	02/24/2003	06/23/2003	Yes	Active	N/A	N/A	Yes
University Hospital of Cincinnati	OH070	2113				2589	01/22/2004	03/03/2004	Yes	Active			
University of Alabama at Birmingham	AL002	2110	06/30/2003	06/30/2003	Yes	2582	05/28/2003	06/30/2003	Yes	Active	N/A	N/A	Yes
University of California, Davis; Sacramento, CA 95817	CA189	2423	07/29/2004	07/29/2004	Yes	2584	10/27/2003	12/09/2003	Yes	Active	N/A	N/A	Yes
University of California San Francisco	CA136	2401	04/10/2002	04/10/2002	Yes	2564	02/27/2002	1st 10	Yes	Active	N/A	N/A	Yes
University of Florida, Gainesville	FL015	3228				2592	02/12/2002	1st 10	Yes	Active			
University of Illinois Medical Center	IL040	8556				2594	08/31/2004	10/21/2004	Yes	Resign - 1/17/02			
University of Maryland	MD015	5702				2599		01/07/2005	Yes	Active			
University of Michigan Medical Center	MI014	2235	06/16/2003	06/16/2003	Yes	2602	01/28/2003	06/23/2003	Yes	Active	N/A	N/A	Yes
University of North Carolina Hospitals	NC007	6501				2608	12/15/2004		Yes	Resign - 10/1/04			
University of Pennsylvania	PA075	2201				2610	02/19/2004	03/17/2004	Yes	Resign-12/2/03			
University of Pittsburgh at Shadyside													
University of Rochester	NY167	0501				2613	02/20/2004	04/08/2004	Yes	Active			
University of Texas Medical Branch, Galveston	TX045	6401	04/10/2002	04/10/2002	Yes	2618	02/11/2002	1st 10	Yes	Active	N/A	N/A	Yes
University of Utah	UT003	8201				2619	05/17/2004	05/17/2004	Yes	Active			
University of Wisconsin	WI020	0801	06/23/2003	06/23/2003	Yes	2622	05/14/2003	06/23/2003	Yes	Active	N/A	N/A	Yes
UT Southwestern Medical Center	TX011	5915				2569	09/01/2004	09/24/2004	Yes	Active			
Virginia Mason Medical Center	WA064	0131				2631	04/30/2004	05/26/2004	No	Active	Repeat - 7/24/03	Yes	
Walke Forest University School of Medicine	NC002	5483				2637	11/14/2003	02/10/2004	Yes	Active			
Washington University	MO011	2101	03/02/2004	03/02/2004	Yes	1075	08/08/2001	1st 10	Yes	Active	N/A	N/A	Yes
Waukesha Memorial Hospital	WI015	7015				2704	06/24/2002	06/23/2003	Yes	Active			
Western Pennsylvania Hospital	PA018	7009				2729	05/17/2004	05/17/2004	Yes	Active			
Wilkes-Barre General Hospital	PA060	1323				2741	10/22/2002	02/06/2004	No	Active	Repeat - 7/13/03	Yes	
William Beaumont Hospital, Royal Oak, MI	MI005	7720	02/27/2003	05/12/2003	Yes	2744	05/07/2003	01/13/2004	Yes	Active	N/A	N/A	Yes
York Cancer Center	PA047	0629				1034	04/04/2004	06/06/2004	Yes	Active			



Radiation Therapy
Oncology Group

Institution Approval Letter for RTOG – 0126



Radiation Therapy Oncology Group

American College of Radiology
1101 Market Street, 14th Floor
Philadelphia, PA 19107
(215) 574-3189
(800) 227-5463 Ext. 4189
(215) 928-0153 Fax

Date

Institution

Dear Dr.:

Since your institution has been credentialed for the IMRT Head and Neck protocols (RTOG 0022 & RTOG 0225) you will be automatically credentialed to participate in the Prostate protocol using IMRT (RTOG 0126 – Phase III Randomized Study of High Dose 3D-CRT/IMRT Versus Standard Dose 3D-CRT/IMRT in Patients Treated for Localized Prostate Cancer). You will not be required to do additional credentialing for the use of IMRT on RTOG 0126.

You are now approved to enter patients onto RTOG Protocol 0126.

Sincerely,

Elizabeth Martin
Director, R.T. Quality Assurance

cc: Physicist
Research Associate
RTOG Randomization
ITC
RPC



Radiation Therapy
Oncology Group

Institution Approval Letter for RTOG – 0126



Radiation Therapy Oncology Group

American College of Radiology
1101 Market Street, 14th Floor
Philadelphia, PA 19107
(215) 574-3189
(800) 227-5463 Ext. 4189
(215) 928-0153 Fax

Date

Institution

Dear Dr.:

The Credentialing process by the Radiological Physics Center (RPC) for irradiating the Head and Neck Phantom using IMRT has been successfully met. The Electronic Data Submission to the Image-Guided Therapy Center (ITC) for RTOG 0126 – Phase III Randomized Study of High Dose 3D-CRT/IMRT Versus Standard Dose 3D-CRT/IMRT in Patients Treated for Localized Prostate Cancer has also been successfully met.

You are now approved to enter patients onto RTOG Protocol 0126.

You are not approved to enter patients onto Head and Neck Protocols using IMRT (RTOG 0022 and RTOG 0225). If in the future you wish to enter patients onto Head and Neck Protocols using IMRT, you will be required to complete the Dry Run test for the Head and Neck IMRT study.

Sincerely,

Elizabeth Martin
Director, R.T. Quality Assurance

cc: Physicist
Research Associate
RTOG Randomization
ITC
RPC



Radiation Therapy
Oncology Group

Institution Approval Letter for RTOG – 0126



Radiation Therapy Oncology Group

American College of Radiology
1818 Market Street, Suite 1600
Philadelphia, PA 19103-3604
(215) 574-3189
(800) 227-5463 Ext. 4189
(215) 928-0153 Fax

Date

Principal Investigator
Institution – RTOG # , NCI # , RTF #
Address
City, State, Zip

Dear Dr.:

The Credentialing process by the Radiological Physics Center (RPC) for irradiating the Pelvic Phantom using IMRT has been successfully met. The Electronic Data Submission to the Image-Guided Therapy Center (ITC) for RTOG 0126 – Phase III Randomized Study of High Dose 3D-CRT/IMRT Versus Standard Dose 3D-CRT/IMRT in Patients Treated for Localized Prostate Cancer has also been successfully met.

You are now approved to enter patients onto RTOG Protocol 0126.

You are not approved to enter patients onto Head and Neck Protocols using IMRT (RTOG 0022 and RTOG 0225). If in the future you wish to enter patients onto Head and Neck Protocols using IMRT, you will be required to irradiate the Head and Neck Phantom using IMRT and complete the Dry Run test for the Head and Neck IMRT study.

Sincerely,

Elizabeth Martin
Director, R.T. Quality Assurance

cc: Physicist
Research Associate
RTOG Randomization
ITC
RPC



Radiation Therapy
Oncology Group

Institution Approval Letter for RTOG – 0126



Radiation Therapy Oncology Group

American College of Radiology
1101 Market Street, 14th Floor
Philadelphia, PA 19107
(215) 574-3189
(800) 227-5463 Ext. 4189
(215) 928-0153 Fax

Date

Institution

Dear Dr. :

The Credentialing process including the Electronic Data Submission to the Image-Guided Therapy Center (ITC) for RTOG 0126 – Phase III Randomized Study of High Dose 3D-CRT/IMRT Versus Standard Dose 3D-CRT/IMRT in Patients Treated for Localized Prostate Cancer has been successfully met.

You are now approved to enter patients onto RTOG Protocol 0126 for 3D-CRT only.

Sincerely,

Elizabeth Martin
Director, R.T. Quality Assurance

cc: Physicist
 Dosimetrist
 Research Associate
 RTOG Randomization
 ITC
 RPC



Radiation Therapy
Oncology Group

Institution Approval Letter for RTOG – 0236



Radiation Therapy Oncology Group

American College of Radiology
1818 Market Street, Suite 1600
Philadelphia, PA 19103-3604
(215) 574-3189
(800) 227-5463 Ext. 4189
(215) 928-0153 Fax

Date

, M.D.

Institution – RTOG # ; NCI # ; RTF #
Department of Radiation Oncology
Address
City, State, Zip

Dear Dr. :

Your institution has successfully completed the Lung Phantom Irradiation Dosimetry Test, Facility Questionnaire, Immobilization/Localization and Respiration Control Systems Test.

You can now enter patients on to RTOG Protocol 0236.

The Dry Run / Rapid Review will be reviewed on the actual case. The dosimetry will be reviewed and the study chair will determine if this and the drawn structures are protocol compliant and sufficient for the patient to go ahead with treatment. Since this test case (Dry Run / Rapid Review) is the first case entered from your institution, the scanning parameters, the structure outline, and the dosimetry will have to be according to protocol in order to pass the Dry Run / Rapid Review **PRIOR TO DELIVERING ANY PROTOCOL TREATMENT**. The plan will be reviewed centrally at the ITC, and suggestions regarding protocol compliance will be forwarded to your institution. The treatment plan for subsequent patients enrolled from your site will not be required to be centrally reviewed prior to treatment, but will be reviewed for protocol compliance at a later date.

However, the Immobilization/Localization and Respiration Control Systems Test must be repeated for the first 4 cases submitted from your institution and the results reviewed by James Galvin, D.Sc., Medical Physics Co-Chair. The data for the first patient entered must be reviewed and approved before you enter a second patient, and the results of the Immobilization/Localization and Respiration Control Systems Study for this patient must be approved prior to entering a third patient. At this point, any additional number of patients can be entered. You will have to send forward the results of the Immobilization/Localization and Respiration Control Systems Study for the third and fourth patients entered. Please refer to the attached information.

Sincerely,

Elizabeth A. Martin
Director, R.T. Quality Assurance

cc: Physicist
Research Associate
James Galvin, D.Sc.
RTOG Randomization
ITC
RPC



Radiation Therapy
Oncology Group

Institution Approval Letter for RTOG – 0236

RTOG Protocol 0236

Immobilization/Localization and Respiration Control Systems Study

This study must be performed on a single patient, and approval received from RTOG Headquarters, before you attempt to enter your first patient on RTOG Protocol 0236. A similar study must be performed for the first patient entered on this protocol, and approval must be received from Headquarters prior to entering a second patient. This same procedure must be followed before entering a third patient. A fourth patient can be entered at the same time as the third, as well as, additional patients can also be entered at this time. However, the results of the Immobilization/Localization and Respiration Control Systems Study for the third and fourth patients entered on this protocol must be sent forward for review as quickly as possible. This information will be analyzed, but no further communication will be sent from RTOG Headquarters except in those situations where problems are detected. If problems are found, you could be asked to stop entering patients until the issue is resolved. In situations where no problems are found, the Immobilization/Localization and Respiration Control Systems Study will be discontinued after you have sent the data forward for the fourth patient you have entered on this protocol.



Radiation Therapy
Oncology Group

RTOG 0236

**Phase II Trial of Stereotactic Body Radiation Therapy
(SBRT) in the Treatment of Patients with Medically
Inoperable Stage I/II Non-Small Cell Lung Cancer**

SCHEMA

R
E
G
I
S
T
E
R

Stereotactic Body Radiation Therapy (SBRT),
20 Gy per fraction for 3 fractions over 1½-2
weeks, for a total of 60 Gy

Tomotherapy




Radiation Therapy
Oncology Group

RTOG 0321

Prostate – Brachytherapy

Credentialing Process Notification





Radiation Therapy
Oncology Group

Institution Approval Letter for RTOG – 0321



Radiation Therapy Oncology Group

American College of Radiology
1818 Market Street, Suite 1600
Philadelphia, PA 19103-3604
(215) 574-3189
(800) 227-5463 Ext. 4189
(215) 928-0153 Fax

Date

Principal Investigator, M.D.
Institution – RTOG # ; NCI # ; RTF #
Department of Radiation Oncology
Address
City, State, Zip

Dear Dr. :

The Credentialing process by the Radiological Physics Center (RPC) for prostate brachytherapy and Electronic Data Submission to the Image-Guided Therapy Center (ITC) for RTOG 0321 – Phase II Trial of Combined High Dose Rate Brachytherapy and External Beam Radiotherapy for Adenocarcinoma of the Prostate has been successfully met.

You are now approved to enter patients onto RTOG Prostate Implant Protocol 0321. A change in Radiation Oncologist, Physicist, treatment planning system, HDR unit will require recredentialing by the RPC and/or ITC.

Sincerely,

Elizabeth A. Martin
Director, R.T. Quality Assurance

cc: Physicist
Research Associate
RTOG Randomization
ITC
RPC
CTSU



Radiation Therapy
Oncology Group

RTOG 0413

A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women with Stage 0, I, or II Breast Cancer

Randomization

GROUP 1*

Whole Breast Irradiation (WBI)

45-50 Gy in 25 (1.8-2.0 Gy) fractions to whole breast, followed by optional boost** to ≥ 60 Gy

GROUP 2*

Partial Breast Irradiation (PBI)***

34 Gy in 3.4 Gy fractions using multi-catheter interstitial brachytherapy

or

34 Gy in 3.4 Gy fractions using MammoSite® balloon catheter

or

38.5 Gy in 3.85 Gy fractions using 3D conformal external beam radiation

For all PBI techniques: RT given to index quadrant only, BID (with a fraction separation of 6 hours), in 5-10 days.



Radiation Therapy
Oncology Group

ATC Meeting Schedule

- Monthly teleconferences are held on the first Wednesday of each month to keep all ATC participants up to date on ongoing activities. Next call on February 2, 2005 at 2:00 CST.
- Bi-weekly teleconferences are held on Friday for RTOG/ITC/RPC Specific issues.
- ATC meeting at the RTOG Semi-Annual Meeting in Phoenix, Arizona, Sheraton Wild Horse Pass Resort and Spa, Thursday, January 20, 2005 at 8:00am – 5:00pm.



Radiation Therapy
Oncology Group

R. T. Quality Assurance Staff



Back Row L/R: Lorraine Quarles; Denise Manfredi; Tammy McGlade;
Betty Martin; Joanne Hunter
Front Row L/R: Darlene Herd; Julie McIlvaine